XILIO THERAPEUTICS, INC.(XLO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XLO XILIO THERAPEUTICS, INC.

Closed 12-11 16:00:00 EST

0.7103

-0.0078

-1.09%

盘后0.7104

+0.0001+0.01%

17:48 EST

High0.7340	Low0.7103	Vol705.38K
Open0.7218	D1 Closing0.7181	Amplitude3.30%
Mkt Cap37.29M	Tradable Cap16.65M	Total Shares52.50M
T/O513.01K	T/O Rate3.01%	Tradable Shares23.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XLO","market":"US","secType":"STK","nameCN":"XILIO THERAPEUTICS, INC.","latestPrice":0.7103,"timestamp":1765486800000,"preClose":0.7181,"halted":0,"volume":705378,"hourTrading":{"tag":"盘后","latestPrice":0.7104,"preClose":0.7103,"latestTime":"17:48 EST","volume":727,"amount":522.0155,"timestamp":1765493305562},"delay":0,"floatShares":23433834,"shares":52500328,"eps":-1.128499,"marketStatus":"Closed","change":-0.0078,"latestTime":"12-11 16:00:00 EST","open":0.7218,"high":0.734,"low":0.7103,"amount":513014.38678134,"amplitude":0.033004,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.128499,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765530000000},"marketStatusCode":5,"adr":0,"listingDate":1634875200000,"exchange":"NASDAQ","adjPreClose":0.7181,"preHourTrading":{"tag":"盘前","latestPrice":0.738,"preClose":0.7181,"latestTime":"09:14 EST","volume":337,"amount":245.03989495,"timestamp":1765462449919},"postHourTrading":{"tag":"盘后","latestPrice":0.7104,"preClose":0.7103,"latestTime":"17:48 EST","volume":727,"amount":522.0155,"timestamp":1765493305562},"volumeRatio":0.836918},"requestUrl":"/m/hq/s/XLO/tweets","defaultTab":"tweets","newsList":[{"id":"2586409363","title":"Xilio Therapeutics Inc. held special shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586409363","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586409363?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:06","pubTimestamp":1764104779,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics Inc. held a special meeting of stockholders on November 21, 2025. Stockholders approved a one-time repricing of certain outstanding employee stock options. Approval was also given for the 2025 Stock Incentive Plan. In addition, stockholders approved the proposal to allow adjournment of the special meeting if necessary.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL6rnmWy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139"],"gpt_icon":0},{"id":"2584492287","title":"Xilio Therapeutics Q3 Net Income USD -16.287 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584492287","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584492287?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:37","pubTimestamp":1763573856,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Xilio Therapeutics Q3 income from operations USD -1.929 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 13-NOV-202512:00:00.157 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD9grDsN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2584929288","title":"Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annua","url":"https://stock-news.laohu8.com/highlight/detail?id=2584929288","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584929288?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:06","pubTimestamp":1763571986,"startTime":"0","endTime":"0","summary":"Nov 7 (Reuters) - Xilio Therapeutics Inc ::*XILIO THERAPEUTICS ANNOUNCES LATE-BREAKING PHASE 2 DATA FOR VILASTOBART IN PATIENTS WITH MSS MCRC AND HIGH PLASMA TUMOR MUTATIONAL BURDEN AT SOCIETY FOR IMM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2RDD4b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139"],"gpt_icon":0},{"id":"2583254807","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Applied Therapeutics (APLT) and Xilio Therapeutics (XLO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583254807","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583254807?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:50","pubTimestamp":1763074211,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Applied Therapeutics (APLT – Research Report) and Xilio Therapeut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-applied-therapeutics-aplt-and-xilio-therapeutics-xlo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-applied-therapeutics-aplt-and-xilio-therapeutics-xlo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","LU0029874061.USD","APLT","HCSG","LU0320765992.SGD","XBI","BK4581","LU0889565916.HKD","BK4139","BK4137","LU0128526141.USD","LU0109394709.USD","XLV","XLO","LABU"],"gpt_icon":0},{"id":"2583608525","title":"Xilio Therapeutics' Q3 collaboration revenue rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2583608525","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583608525?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:42","pubTimestamp":1763037734,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics' Q3 collaboration revenue risesOverviewXilio Q3 collaboration revenue rises to $19.1 mln from $2.3 mln year-over-yearNet loss for Q3 widens to $16.3 mln from $14.0 mln year-over-yea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0HR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2583604567","title":"BRIEF-Xilio Therapeutics Q3 Net Income USD -16.287 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583604567","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583604567?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037046,"startTime":"0","endTime":"0","summary":"BRIEF-Xilio Therapeutics Q3 Net Income USD -16.287 Million\n\n\nNov 13 (Reuters) - Xilio Therapeutics Q3 income from operations USD -1.929 million.\n\nQ3 operating expenses USD 20.995 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX15AA63:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2583671415","title":"Xilio Therapeutics Inc - Anticipates Cash Runway Into Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2583671415","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583671415?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX15AA63:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2583679215","title":"Press Release: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583679215","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583679215?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037000,"startTime":"0","endTime":"0","summary":"Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden. Presented Phase 1 data at SITC for efarindodekin alfa showing promising monotherapy anti-tumor activity and generally well-tolerated safety profile in patients with advanced solid tumors. Announced new preclinical data at SITC for masked T cell engager programs supporting best-in-class potential and showing efficient masking, potent anti-tumor activity and broad therapeutic index. Anticipate cash runway into the first quarter of 2027. WALTHAM, Mass., Nov. 13, 2025  -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the third quarter ended September 30, 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","LU0210528500.USD","BK4113","MSS","LU0053666078.USD","BK4080","BK4022","SITC","BK4539","LU2487616109.SGD","BK4585","R","BK4007","BK4107","ORR","XLO","BK4231","LENZ","BK4139","BK4588","TMB","L"],"gpt_icon":0},{"id":"2581881331","title":"Xilio Therapeutics presents new data across portfolio at SITC","url":"https://stock-news.laohu8.com/highlight/detail?id=2581881331","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581881331?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:21","pubTimestamp":1762525283,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics (XLO) announced new data across its portfolio, including preclinical data highlighting the potential for Xilio’s masked T cell e...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xilio-therapeutics-presents-new-data-across-portfolio-at-sitc-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xilio-therapeutics-presents-new-data-across-portfolio-at-sitc-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LENZ","BK4539","XLO"],"gpt_icon":0},{"id":"2581881389","title":"Xilio Therapeutics announces new data on Phase 2 trial of vilastobart","url":"https://stock-news.laohu8.com/highlight/detail?id=2581881389","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581881389?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:20","pubTimestamp":1762525251,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics (XLO) announced new data from its ongoing Phase 2 clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced anti-CTL...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xilio-therapeutics-announces-new-data-on-phase-2-trial-of-vilastobart-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xilio-therapeutics-announces-new-data-on-phase-2-trial-of-vilastobart-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LENZ","BK4539","XLO"],"gpt_icon":0},{"id":"2581488650","title":"Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients With Mss Mcrc and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40TH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581488650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581488650?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:05","pubTimestamp":1762524300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA4NN4CP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2581628886","title":"Press Release: Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581628886","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581628886?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:05","pubTimestamp":1762524300,"startTime":"0","endTime":"0","summary":"40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden . Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need. \"These compelling new Phase 2 data for vilastobart in combination with atezolizumab demonstrated a 40% objective response rate in heavily pre-pretreated patients with MSS mCRC without liver metastases and with high plasma TMB, signifying an important advance in our understanding of response to novel immunotherapy in MSS mCRC,\" said Katarina Luptakova, M.D., chief medical officer of Xilio. \"In addition, these data showed a statistically significant correlation between plasma-based TMB and response. We estimate that approximately 55% of patients with MSS CRC have high plasma TMB, representing a meaningful patient population who could ultimately benefit from combination treatment with vilastobart and a substantially greater prevalence of patients w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4535","BK4552","BK1103","BK4232","BK4007","BK4571","IE00B12V2V27.USD","LENZ","LU0456842615.SGD","IE00BYTNYN87.SGD","MSS","LU1023057109.AUD","LU0359201612.USD","LU2487616109.SGD","SITC","BK4585","BK4563","BK4588","SG9999011746.SGD","R","BK1541","IE00BYQNZ168.SGD","LU0210528500.USD","IE0003795394.USD","BK4107","BK4526","LU2039709279.SGD","TMB","BK4509","IE0003851619.USD","BK4139","L","LU0053666078.USD","LU0359202008.SGD","BK4539","BK4565","BK4231","BK4548","01308","BK4080","ORR","TME","01698","BK4531","XLO","BK4108","BK4113"],"gpt_icon":0},{"id":"2581532886","title":"Xilio Therapeutics Unveils Promising Phase 1 Data for Tumor-Activated IL-12 in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2581532886","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581532886?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:01","pubTimestamp":1762524093,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics, Inc. has announced new data from its pipeline of tumor-activated immuno-oncology therapies at the Society for Immunotherapy of Cancer  40th Annual Meeting, held from November 5-9, 2025. The company presented preclinical data on its masked T cell engager platform, as well as clinical data from its ongoing studies. Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, and Phase 2 data related to circulating tumor DNA  for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, were showcased during the event. Xilio also announced development milestones for its masked T cell engager programs, with plans to advance at least two candidates into IND-enabling studies and submit IND applications in 2027. Copies of the presentations are available on the Xilio Therapeutics website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDLYV4jz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4112","BK4588","LU2210150020.SGD","LU0314104364.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","XLO","BK4139","NDAQ","LU2210149790.SGD","BK4585"],"gpt_icon":0},{"id":"2580225553","title":"Xilio Therapeutics Grants Stock Options to New Employee Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2580225553","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580225553?lang=en_us&edition=fundamental","pubTime":"2025-11-04 05:30","pubTimestamp":1762205418,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics Inc. has granted a non-qualified stock option to purchase 5,700 shares of its common stock to a new employee. The options have an exercise price of $0.7967 per share, matching the closing price on October 31, 2025. The options vest 25% after one year of employment, with the remaining 75% vesting in 36 equal monthly installments, and carry a ten-year term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL2wRy4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU0314104364.USD","NDAQ","BK4588","BK4139","BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","XLO","BK4585","LU2095319765.USD"],"gpt_icon":0},{"id":"2580719290","title":"Xilio Therapeutics Inc  expected to post a loss of 3 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580719290","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580719290?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:31","pubTimestamp":1762173115,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics Inc  expected to post a loss of3cents a share - Earnings Preview Xilio Therapeutics Inc XLO.OQ XLO.O is expected to  show a rise in quarterly revenue when it reports  results on Nov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF0Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2579142463","title":"Xilio Therapeutics Announces Phase 2 Data for Vilastobart in MSS mCRC at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579142463","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579142463?lang=en_us&edition=fundamental","pubTime":"2025-10-30 21:02","pubTimestamp":1761829368,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics Inc. announced that it will present new Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4 therapy, at the Society for Immunotherapy of Cancer  40th Annual Meeting, scheduled for November 5-9, 2025. The late-breaking presentation will focus on response rates for vilastobart in combination with atezolizumab in patients with microsatellite stable metastatic colorectal cancer  who have high plasma tumor mutational burden. The data will be available in a poster session on November 7, 2025, and will also be posted on the Xilio Therapeutics website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDLbG66lP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4139","XLO","BK4585","BK4588"],"gpt_icon":0},{"id":"2574102232","title":"Xilio Therapeutics Inc announces date for special stockholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2574102232","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574102232?lang=en_us&edition=fundamental","pubTime":"2025-10-11 04:04","pubTimestamp":1760126688,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL4qxyRl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2572654500","title":"Xilio Therapeutics Announces New Clinical Data for Tumor-Activated Immunotherapies at SITC 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2572654500","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572654500?lang=en_us&edition=fundamental","pubTime":"2025-10-03 21:00","pubTimestamp":1759496424,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics Inc., a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has announced multiple upcoming presentations at the Society for Immunotherapy of Cancer  40th Annual Meeting, scheduled for November 6-9, 2025, at the Gaylord National Convention Center in National Harbor, Maryland. The company will present new clinical data on vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, and efarindodekin alfa , a tumor-activated IL-12. Additionally, preclinical data on Xilio's masked T cell engager programs will be showcased. Specific poster presentations include an analysis of ctDNA as a potential surrogate biomarker for response to combination vilastobart and atezolizumab in heavily pretreated microsatellite stable metastatic colorectal cancer, pharmacodynamic data from the first-in-human phase 1 study of XTX301 in advanced solid tumors, and data on masked T cell engagers designed for synthetic anti-tumor immunity","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL381D2t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","XLO","IE00B3QW5Z07.USD","BK4588","NDAQ","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD"],"gpt_icon":0},{"id":"2572500636","title":"Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40TH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2572500636","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572500636?lang=en_us&edition=fundamental","pubTime":"2025-10-03 21:00","pubTimestamp":1759496400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nTUA5GWDP3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XLO","BK4139"],"gpt_icon":0},{"id":"2572502929","title":"BRIEF-Xilio Therapeutics Transfers Listing Of Co's Common Stock To Nasdaq Capital Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2572502929","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572502929?lang=en_us&edition=fundamental","pubTime":"2025-10-03 20:03","pubTimestamp":1759493034,"startTime":"0","endTime":"0","summary":"BRIEF-Xilio Therapeutics Transfers Listing Of Co's Common Stock To Nasdaq Capital MarketOct 3  - SEC Filing:XILIO THERAPEUTICS - TRANSFERS LISTING OF CO'S COMMON STOCK TO NASDAQ CAPITAL MARKET,EFFECTIVE OCTOBER 6 - SEC FILINGSource text: [ID:n0001193125-25-229231]Further company coverage: XLO.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nFWN3VJ0JA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xiliotx.com","stockEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.1077},{"period":"3month","weight":-0.0159},{"period":"6month","weight":0.0841},{"period":"1year","weight":-0.3257},{"period":"ytd","weight":-0.2481}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.031885},{"month":2,"riseRate":0.5,"avgChangeRate":0.057614},{"month":3,"riseRate":0.25,"avgChangeRate":-0.049721},{"month":4,"riseRate":0.5,"avgChangeRate":-0.109931},{"month":5,"riseRate":0.5,"avgChangeRate":0.052494},{"month":6,"riseRate":0,"avgChangeRate":-0.163729},{"month":7,"riseRate":0.5,"avgChangeRate":0.01036},{"month":8,"riseRate":0.5,"avgChangeRate":-0.060444},{"month":9,"riseRate":0.5,"avgChangeRate":0.039039},{"month":10,"riseRate":0.5,"avgChangeRate":0.099935},{"month":11,"riseRate":0.2,"avgChangeRate":-0.160439},{"month":12,"riseRate":0.4,"avgChangeRate":-0.088655}],"exchange":"NASDAQ","name":"XILIO THERAPEUTICS, INC.","nameEN":"XILIO THERAPEUTICS, INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"XILIO THERAPEUTICS, INC.(XLO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest XILIO THERAPEUTICS, INC.(XLO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"XILIO THERAPEUTICS, INC.,XLO,XILIO THERAPEUTICS, INC.股票,XILIO THERAPEUTICS, INC.股票老虎,XILIO THERAPEUTICS, INC.股票老虎国际,XILIO THERAPEUTICS, INC.行情,XILIO THERAPEUTICS, INC.股票行情,XILIO THERAPEUTICS, INC.股价,XILIO THERAPEUTICS, INC.股市,XILIO THERAPEUTICS, INC.股票价格,XILIO THERAPEUTICS, INC.股票交易,XILIO THERAPEUTICS, INC.股票购买,XILIO THERAPEUTICS, INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"XILIO THERAPEUTICS, INC.(XLO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest XILIO THERAPEUTICS, INC.(XLO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction